{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:06:07Z","timestamp":1785535567700,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.msard.2024.105729","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:44:06Z","timestamp":1718307846000},"page":"105729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-121X","authenticated-orcid":false,"given":"Patrick","family":"Schindler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bellmann-Strobl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Jarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2024.105729_bib0001","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1007\/s00415-021-10914-x","article-title":"Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"269","author":"Akaishi","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105729_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.668606","article-title":"A Kinetic Model for Blood Biomarker Levels After Mild Traumatic Brain Injury","volume":"12","author":"Azizi","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105729_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105729_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting Linear Mixed-Effects Models Using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Softw."},{"issue":"3","key":"10.1016\/j.msard.2024.105729_bib0005","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2024.105729_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209303","article-title":"Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease","volume":"102","author":"Cacciaguerra","year":"2024","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2024.105729_bib0007","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.26731","article-title":"Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?","volume":"94","author":"Chen","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105729_bib0008","article-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988","journal-title":"L. Erlbaum Associates.J"},{"issue":"2","key":"10.1016\/j.msard.2024.105729_bib0009","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105729_bib0010","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study","author":"Gastaldi","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2024.105729_bib0011","doi-asserted-by":"crossref","first-page":"fcad063","DOI":"10.1093\/braincomms\/fcad063","article-title":"Early blood neurofilament light chain and myelin oligodendrocyte glycoprotein antibody levels associate with different disease courses of myelin oligodendrocyte glycoprotein-associated disease in children","volume":"5","author":"Horellou","year":"2023","journal-title":"Brain Commun."},{"issue":"6","key":"10.1016\/j.msard.2024.105729_bib0012","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/13524585211063756","article-title":"Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: longitudinal assessment of serum neurofilament light chain","volume":"28","author":"Hyun","year":"2022","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.105729_bib0013","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation."},{"issue":"1","key":"10.1016\/j.msard.2024.105729_bib0014","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation."},{"issue":"1","key":"10.1016\/j.msard.2024.105729_bib0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.msard.2024.105729_bib0016","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12974-015-0418-1","article-title":"Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis","volume":"12","author":"Keller","year":"2015","journal-title":"J. Neuroinflammation."},{"issue":"10","key":"10.1016\/j.msard.2024.105729_bib0017","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.105729_bib0018","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1212\/NXI.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"13","key":"10.1016\/j.msard.2024.105729_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest Package: tests in Linear Mixed Effects Models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.msard.2024.105729_bib0020","article-title":"Equivalence tests: a practical primer for t-tests, correlations, and meta-analyses","volume":"1","author":"Lakens","year":"2017","journal-title":"Soc. Psychol. Personal. Sci."},{"issue":"5","key":"10.1016\/j.msard.2024.105729_bib0021","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jnc.15549","article-title":"Serum neurofilament light chain in adult and pediatric patients with myelin oligodendrocyte glycoprotein antibody-associated disease: correlation with relapses and seizures","volume":"160","author":"Luo","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.msard.2024.105729_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102833","article-title":"NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders","volume":"50","author":"Mariotto","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105729_bib0023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jamiaopen\/ooy012","article-title":"tableone: an open source Python package for producing summary statistics for research papers","volume":"1","author":"Pollard","year":"2018","journal-title":"JAMIa Open."},{"key":"10.1016\/j.msard.2024.105729_bib0024","article-title":"Time to steroids impacts visual outcome of optic neuritis in MOGAD","author":"Rode","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2024.105729_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMa Netw. Open."},{"issue":"1","key":"10.1016\/j.msard.2024.105729_bib0026","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J. Neuroinflammation."},{"issue":"2","key":"10.1016\/j.msard.2024.105729_bib0027","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1352458520907900","article-title":"Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies","volume":"27","author":"Sechi","year":"2021","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.105729_bib0028","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","article-title":"Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"94","author":"Spagni","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2024.105729_bib0029","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/s12883-022-02986-7","article-title":"Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study","volume":"22","author":"Sperber","year":"2022","journal-title":"BMC. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105729_bib0030","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.105729_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2024.105729_bib0032","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105729_bib0033","doi-asserted-by":"crossref","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","author":"Wickham","year":"2019","journal-title":"J. Open. Source Softw."},{"key":"10.1016\/j.msard.2024.105729_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-330901","article-title":"Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study","author":"ZhangBao","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:21:29Z","timestamp":1723605689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824003067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":34,"alternative-id":["S2211034824003067"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105729","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105729"}}